Mohan Bala
Corporate Officer/Principal en MERSANA THERAPEUTICS, INC. .
Fortuna: 62 953 $ al 31/03/2024
Perfil
Mohan Bala's career history includes current and former positions as well as education.
Currently, Dr. Bala is the Chief Development Officer & Senior Vice President at Mersana Therapeutics, Inc. Prior to this, Dr. Bala held the position of Chief Operating Officer at Constellation Pharmaceuticals, Inc. and Vice President of Lead Development Program at Tesaro, Inc. Dr. Bala's education includes an MBA and a doctorate from The University of Chicago.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 16/01/2024 | 14 052 ( 0.01% ) | 62 953 $ | 31/03/2024 |
Cargos activos de Mohan Bala
| Empresas | Cargo | Inicio |
|---|---|---|
| MERSANA THERAPEUTICS, INC. | Corporate Officer/Principal | 25/10/2021 |
Antiguos cargos conocidos de Mohan Bala.
| Empresas | Cargo | Fin |
|---|---|---|
| TESARO INC | Corporate Officer/Principal | - |
| CONSTELLATION PHARMACEUTICALS, INC. | Chief Operating Officer | - |
Formación de Mohan Bala.
| The University of Chicago | Doctorate Degree |
Experiencias
Funciones ocupadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| MERSANA THERAPEUTICS, INC. | Health Technology |
| Empresas privadas | 2 |
|---|---|
Tesaro, Inc.
 Tesaro, Inc. Pharmaceuticals: MajorHealth Technology TESARO, Inc. is an oncology-focused biopharmaceutical company, which engages in the research and development of biopharmaceutical products. The firm offers Niraparib products. The company was founded by Leon Oliver Moulder, Jr., Mary Lynne Hedley, and Richard J. Rodgers on March 26, 2010 and is headquartered in Waltham, MA. | Health Technology |
Constellation Pharmaceuticals, Inc.
 Constellation Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics in the field of epigenetics. The firm utilizes epigenetics platform, which enables to validate targets and generate small molecules against these targets that selectively modulate gene expression in tumor and immune cells to drive anti-tumor activity. Its product include CPI-0610, CPI-1205, and CPI-0209. The company was founded by Danny Reinberg, David Allis, and Yang Shi on January 11, 2008 and is headquartered in Cambridge, MA. | Health Technology |
- Bolsa de valores
- Insiders
- Mohan Bala
